APA (7th ed.) Citation

Y, W., Y, Z., W, Y., X, Z., L, X., Y, S., . . . Z, M. (2026). Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: An exploratory real-world multicenter cohort study. Frontiers in immunology, 17, 1825584. https://doi.org/10.3389/fimmu.2026.1825584

Chicago Style (17th ed.) Citation

Y, Wu, et al. "Comparative Efficacy of Ripertamab, Rituximab, and Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy: An Exploratory Real-world Multicenter Cohort Study." Frontiers in Immunology 17 (2026): 1825584. https://doi.org/10.3389/fimmu.2026.1825584.

MLA (9th ed.) Citation

Y, Wu, et al. "Comparative Efficacy of Ripertamab, Rituximab, and Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy: An Exploratory Real-world Multicenter Cohort Study." Frontiers in Immunology, vol. 17, 2026, p. 1825584, https://doi.org/10.3389/fimmu.2026.1825584.